Luca Benatti - Net Worth and Insider Trading
Luca Benatti Net Worth
The estimated net worth of Luca Benatti is at least $92,561 dollars as of 2023-06-09. Luca Benatti is the Director of Intercept Pharmaceuticals Inc and owns about 7,556 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $92,561. Details can be seen in Luca Benatti's Latest Holdings Summary section.
Transaction Summary of Luca Benatti
Luca Benatti Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Luca Benatti owns 1 companies in total, including Intercept Pharmaceuticals Inc (ICPT) .
Click here to see the complete history of Luca Benatti’s form 4 insider trades.
Insider Ownership Summary of Luca Benatti
|Ticker||Comapny||Transaction Date||Type of Owner|
|ICPT||Intercept Pharmaceuticals Inc||2020-05-28||director|
Luca Benatti Latest Holdings Summary
Luca Benatti currently owns a total of 1 stock. Luca Benatti owns 7,556 shares of Intercept Pharmaceuticals Inc (ICPT) as of May 14, 2019, with a value of $92,561.
Latest Holdings of Luca Benatti
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|ICPT||Intercept Pharmaceuticals Inc||2019-05-14||7,556||12.25||92,561|
Holding Weightings of Luca Benatti
Luca Benatti Form 4 Trading Tracker
According to the SEC Form 4 filings, Luca Benatti has made a total of 1 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Intercept Pharmaceuticals Inc is the acquisition of 1,200 shares on May 14, 2019, which cost Luca Benatti around $100,200.
Insider Trading History of Luca Benatti
Luca Benatti Trading Performance
GuruFocus tracks the stock performance after each of Luca Benatti's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Luca Benatti is -24.55%. GuruFocus also compares Luca Benatti's trading performance to market benchmark return within the same time period. The performance of stocks bought by Luca Benatti within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Luca Benatti's insider trading performs compared to the benchmark.
Performance of Luca Benatti
Average Relative Return
|1 Month||3 Months||6 Months||1 Year||2 Years||3 Years|
|Relative Return to S&P 500(%)||-10.18||-24.77||-13.52||-5.2||-75.53||-53.32|
Luca Benatti Ownership Network
Ownership Network List of Luca Benatti
Ownership Network Relation of Luca Benatti
Luca Benatti Owned Company Details
What does Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Who are the key executives at Intercept Pharmaceuticals Inc?
Luca Benatti is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .
Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intercept Pharmaceuticals Inc Insider Transactions
Luca Benatti Mailing Address
Above is the net worth, insider trading, and ownership report for Luca Benatti. You might contact Luca Benatti via mailing address: C/o Intercept Pharmaceuticals, Inc., 450 West 15th Street, Suite 505, New York Ny 10011.